Michael Hofman, Director of Prostate Cancer Theranostics and Imaging Centre of Excellence (ProSTIC) at Peter MacCallum Cancer Centre, shared a post on X:
“It’s been an extra-ordinary year for our ProsTIC Theranostics program at Peter MacCallum Cancer Centre – highlights from the year:
- First-in-human Terbium-161 PSMA (VIOLET study): Dual beta/Auger emitter results presented at ASCO, SNMMI and co-published in The Lancet Oncology – opening a new chapter in PSMA theranostics
- AlphaBet trial: Combination Lutetium-177 PSMA plus Radium-223 alpha therapy presented at ESMO
- PRIMARY2 fully recruited: Completion of a 660-patient Australian randomised phase III PSMA PET imaging trial. Results anticipated in 2026.
- Next-generation total-body PET: Installation of the first GE Healthcare Omni 128 cm Total-Body PET at Peter Mac – imaging patients with extraordinary image quality. Over 11,500 PET/CT scans performed in 2025
- First-in-class peptides against new targets: promising small-animal PET imaging providing confidence to progress toward first-in-human studies
- Liquid biomarkers for precision theranostics: defining the role of ctDNA to predict benefit from Lu-PSMA therapy – results from TheraP and the ProsTIC registry (Nature Medicine, European Urology)
- Global knowledge exchange: international webinars delivered with Prostate Cancer Foundation and GU Cast | Urology podcast! – 1,000+ registrants from 57 countries
- A major clinical milestone: treating 500 patients on the ProsTIC Lu-177 PSMA-617 clinical registry, enabling real-world outcome analysis at scale.
- Training the next generation of Theranostic researchers, PhDs – Renu Eapen (nuclear urology), James Buteau (nuclear medicine), Louise Kostos (nuclear oncology), David Chen (commencing 2026 with NHMRC scholarship)
- Sustained research investment: >$15 million in new funding
Grateful to our exceptional collaborators:
- In 2025: Declan Murphy (Urology), Arun Azad (Medical Oncology), Shankar Siva (Radiation Oncology), Mohammad Haskali (Radiopharmaceutical Sciences), Luc Furic (Translational Research), Anna Trigos (Computational Biology), Price Jackson (Medical Physics) and Annette Van Der Heyden (Program Manager). Many Many Young Investigators!
- Major funders: Australian Cancer Research Foundation, Australian National Imaging Facility, Prostate Cancer Foundation
- Key industry collaborators: Isotopia Molecular Imaging (VIOLET), GE HealthCare (Omni128), Bayer AG (AlphaBet), Novartis Cancer (Registry, LuCab), AdvanCell Isotopes (Pb-212)
- ANZUP, Theranostics AANMS
- Our patients who drive our research
Onward to 2026… I’m shortly heading to Memorial Sloan Kettering Cancer Center for a 6 month sabbatical … to my NY and USA colleagues – please reach directly out if you want to meet and discuss collaborations.”
Proceed to the video attached to the post.
More posts featuring Michael Hofman.